Valette (Dienogest/EE30, BAY86-5038)
DrugOral contraceptive extended cycles
NCT Number: NCT00302666
The aim of this study is to evaluate bleeding pattern, cycle control, contraceptive efficacy and safety of this oral contraceptive in two different regimens of intake.
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Phase 3
Eberbach, Baden-Wurttemberg, Germany
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral contraceptive extended cycles
Bayer
Industry
Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Different Regimens of Intake (Four Extended Cycles of 84 Days Each Versus the Conventional Regimen of 21 Days) in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01318005
Oral Contraceptive
Los Angeles, California, United States
View Trial DetailsNCT01291004
Follicle Count, Follicle Development
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT01388491
Cardiovascular Diseases, Embolism and Thrombosis
Essen, Germany
View Trial DetailsNCT00972439
Oral Contraceptive
Los Angeles, California, United States
View Trial Details